Rustam Gilfanov: Stem cells, What Science Knows And Expects

Rustam Gilfanov
Rustam Gilfanov Rustam Gilfanov

Clearly, stem cells are not a cure-all: but what can science do to bring them closer to this ideal?

Exactly 40 years ago, the future Nobel Prize winner Martin Evans published his study on mouse embryos’ stem cells and their medical potential [1]. His research revolutionized biomedicine, as it envisioned the future, in which any damaged tissue could be replaced by a new one, grown in vitro from the patient's cells.

What has changed since 1981? Are we approaching the times when regeneration and artificial organs become a reality? Or did the research tendencies change, with regeneration going out of style? Here, I will try to outline several major trends.

Once again, what makes stem cells so important?

There are two types of stem cells: embryonic and tissue cells.

The embryonic ones can transform into any other cell type. A fetus consists of these very cells during days 3-5 of gestation. And if kept in a special environment, they can divide almost infinitely, while remaining unchanged.

A small number of tissue stem cells can be found in the organs of adult people. They help to restore damaged tissues and can transform into one particular cell type only. Eventually, scientists have learned to make embryonic cells’ analogs out of them that can be used for growing various tissue types. Since the days of Martin Evans, they have been called pluripotent stem cells.

The discovery of these two cell types led to the rapid development of regenerative medicine. The pathologies it could potentially cope with include strokes, cardiovascular diseases, diabetes, Parkinson’s and Alzheimer’s, ALS, osteoarthritis, severe burns, and even various oncological diseases. However, we must admit that as of 2021, regenerative medicine has been unable to achieve such outstanding results.

Where were stem cells really useful?

In 1998, the technology was discovered that allowed to “separate” embryonic stem cells from the organism and grow them in vitro, i.e., literally transform them into tissues of any type [2]. Thus, regenerative medicine moved from theory to practice, as it became possible to work with stem cells in laboratory conditions.

Stem cells are already contributing to science — not directly as a therapy method, but implicitly as a way to study various important aspects. For instance, by watching them develop into bone, nerve, or some other cells, medics and scientists get a better understanding of how hereditary diseases are progressing.

Besides, pharmacologists apply stem cells for testing new medications. For human trials to start, a drug must be proven to be safe. To do this, tissues originated from stem cells are used: e.g., it is possible now to grow nerve cells for testing a new medication against neurological diseases. Such tests can reveal positive or adverse effects in advance and, in theory, accelerate randomized controlled trials by helping to avoid lengthy and burdensome legal procedures. However, this method remains more expensive than traditional, albeit slow, enrollment of candidates.

Why are stem cells still not a thing?

Despite outstanding research results, medics actively apply only one method of stem cell therapy — bone marrow transplants for blood cancer treatment.

Many constraints hinder regenerative medicine breakthroughs. One of them is unpredictability: the researchers must be sure that stem cells will transform into the tissue they are planning to get. Also, medics need to learn to regulate the development and multiplication of stem cells to prevent an uncontrolled division of cells that causes malignant tumors.

Besides, the immune system may attack embryonic stem cells mistaking them for invaders, while modern medicine is lacking tools for adjusting this immune response. We can see the consequences of this in real time during the COVID-19 pandemic, with thousands of people dying because of the aggressive and unbridled immune response, not because of the direct impact of SARS-CoV-2.

It must also be taken into consideration that current technologies are demonstrating a lot of side effects. Patients with multiple sclerosis, who received stem cell treatment, suffered from low platelet and white blood cell counts, infections, and toxic liver damage [3].

Another problem is the expensiveness of this method. One session of the MS treatment listed above cost 40, 000 pounds.

Finally, there is another constraint that still cannot be overcome and is related to technological and ethical issues. The revolutionary 1998 report that I mentioned earlier stated the embryo that “lent” stem cells to the researchers was destroyed. From the humanistic perspective, we are walking the thin line between “killing a potential living being for an already existing one” and “simply manipulating with cells”.

In 2006, Japanese researcher Shinya Yamanaka offered a solution to this dilemma: he developed the so-called induced Pluripotent Stem Cells (iPSC), de facto providing an analog to embryonic cells that is based on somatic cells of adult persons. In this case, there is no need to destroy an embryo; for this achievement, professor Yamanaka has been rightfully awarded the Nobel Prize in Physiology or Medicine. Nevertheless, while solving one problem, this method actually caused a new one.

Scientists have found that iPSCs have a high potential for causing tumors — and the risk of malignancy is too serious to start using these cells for therapeutic purposes.

Thus, the only morally acceptable method of using embryonic stem cells available to us at the moment is using mouse embryos’ cells — this technology has been tested and is relatively well-developed, even though it remains quite expensive [4].

What are the achievements of stem cell treatment?

We have to admit that now, 40 years since Martin Evans’ discovery and 23 years since the first successful in vitro stem cell manipulations, reproductive medicine is still taking its baby steps. There are many research programs but only a few technologies made it to “mass production”. Yet even these intermediate results seem astonishing.

For example, in 2016 a team of scientists from Greece and the UK attempted to regenerate muscle tissue of infarction patients by transplanting myocardium cells that had been grown in the lab [5]. As a result, cardiac callosity was reduced by 40%. Before that, such damages had been considered untreatable. However, only 11 people took part in the research and this number is too small to draw any firm conclusions.

Scientists are gradually improving the technologies they implement. Here is an example. The immune system may attack the stem cell transplant, mistaking it for a foreign object. This is why medics are working on culturing cells that do not provoke an immune response. In 2020, researchers from Karolinska Institutet and St. Eric Eye Hospital (Sweden) found a way to improve the production of retina cells from embryonic stem cells for treating blindness among aged patients [6]. They managed to alter the cells so that they can hide from the immune system instead of being destroyed by it.

Another promising technology involves stem cells already existing in the body. During an experiment conducted by the University of Illinois researchers, nanoparticles with molecules stimulating stem cell activity were introduced to damaged muscles of rats [7]. As a result, muscles were recovering faster and the animals were able to walk longer distances, compared to traditional treatment.

Standalone cases have also been a huge success. In 2019, Japanese medics, for the first time in history, transplanted hepatocytes grown from human embryonic stem cells to a six-day-old baby: the child’s liver did not have the enzyme that transforms nitrogen-containing breakdown products into urea. Thus, a rare congenital disease was blocked [8]. Scientists think that stem-cell hepatocyte transplantation, with its effectiveness and safety tested by this case, can be applied in the future not only for treating congenital urea cycle disorders but also for helping patients who need to wait for a liver donor.

One year prior, in 2018, the scientists de facto grew a human heart from iPSCs. They cultured a contracting myocardial tissue, with its characteristics (gene expression, structure, etc.) identical to the functioning cardiac tissue of an adult person [9]. Although it is impossible to transplant this “artificial heart” to a patient, the experiment turned out to be useful for testing new drugs.

In 2020, 13 patients with spinal cord injuries received an experimental therapy that involved stem cells. Because of the injuries, they suffered from such neurological symptoms as loss of motor function and body sensitivity, bowel and bladder dysfunction, etc. All patients were given intravenously several dosages of mesenchymal stem cells (multipotent cells capable of transforming into various cell types including neurons) cultured from their own marrow. 12 out of 13 participants showed significant improvement in the following six months — and these results are extremely encouraging [10].

Experiments on rats conducted by Swedish researchers led to an even more impressive outcome: the scientists achieved the post-stroke recovery of animals’ neurons by using iPSCs. To do this, they reprogrammed human skin cells and the synthesized neurons quickly adapted to the neural system. Six months after the transplantation, all signs of brain damage caused by the stroke have disappeared and the rats regained their motor functions and sensitivity to the touch [11]. However, the impact on test subjects’ “personality” cannot be estimated — this can become a major constraint for performing such potential “transplantations” on humans.

Summing up, almost every week a new article boasting successful stem cell research can be found in scientific journals. Yet all these experiments do not bring us closer to a victory over any severe disease or at least prove that regenerative medicine is reaching a new level. What is the matter, then?

What challenges is regenerative medicine facing?

1. The stem cell market reached 14.7 billion dollars in 2020 and is estimated to grow up to 26.4 billion by 2026. In other words, it is expected to double in the next five years. This is a very favorable forecast and investors are stocking up shares of stem cell research companies, boosting their value and expanding the market.

Do you get what I mean? The belief in stem cells and their ability to solve almost any medical problem has turned this market into a bubble that can burst any moment, putting these exorbitant investments to waste. What is worse, this crisis will suspend ongoing medical research, possibly stymieing The One that could give us a really effective and scalable technology for treating cancer or cardiovascular diseases.

Market players, investors, and stem cell researchers themselves should lower their expectations so that the bubble stops growing on high hopes alone. The value of shares and investments must grow according to actual discoveries and successes — this will be more beneficial to science than any boom caused by ungrounded attention. This is what happened to the revolutionary CRISPR-Cas technology: from the big business perspective, it came out of nowhere; yet now it is really changing the world.

2. The stem cell industry (both investors and researchers) need to focus on the COVID-19 pandemic. Some studies are already attempting to fight COVID-19 with iPSC technologies; yet even if they fail (we do not have effective medications against various viruses and it is unlikely we get the ones treating SARS-CoV-2), it is necessary to seize the moment.

This may sound too calculated or cynical, but the attention of governments, businesses, and the public to the healthcare industry will not always be as high as it has been during the pandemic. Now it is the right moment to attract money, technologies, and human resources — by the mid-2020s, if COVID-19 is taken under control, they can be successfully “transferred” to other areas of medicine.

3. It is essential to take advantage of information technologies. Experiments on mice are unable to quickly assess various mechanisms of stem cell functioning, especially given the rigid ethical restrictions on human testing. The successes and achievements that I mentioned in this article, as well as thousands of others, are just a drop in the ocean compared to what is required to help regenerative medicine evolve into a fully functioning discipline.

Present-day computer models offer unique opportunities for in silico research — technically, we already have reliable “virtual patients” for testing even such complex methods as cell “reprogramming”. “Virtual clinical trials” remove ethical constraints and enable the quick collection of data available to scientists from all over the world, who are conducting similar studies. There is no need to get rid of classical research methods, yet widespread in silico technologies can accelerate stem cell research multiple times.

4. Even before Dolly the sheep was born, people had been debating on the moral aspects of cloning living creatures, especially humans. Nowadays, legal restrictions on such procedures are imposed in many countries, while regulation of stem cells is still in its embryonic stage — with no reprogramming in sight.

Specialists from various industries — healthcare, law, IT, pharmaceutics, and fundamental science including humanities (e.g., researchers on morality, ethics, and philosophical notions of the digital age) — need to join their efforts and set the adequate rules of this game. What stem cells can be used and in what situations? Which “reprogramming” types are acceptable and which are not? What are the moral limits of clinical trials and therapy involving stem cells? Lots of questions still need answering — and provisioning these answers in codes and guidelines.

To truly make stem cells and regenerative medicine the next big thing, instead of becoming just another fashionable trend or a market bubble, we need to work this out. And we need to do it together.

Disclaimer: The views and opinions expressed by the contributor are those of the authors and do not necessarily reflect the official policy or position of IBTimes.com

About the Author

Rustam Gilfanov is an IT entrepreneur and a venture partner of the LongeVC fund.

References:

1. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981 Jul 9;292(5819):154-6. doi: 10.1038/292154a0. PMID: 7242681.

2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998 Nov 6;282(5391):1145-7. doi: 10.1126/science.282.5391.1145. Erratum in: Science 1998 Dec 4;282(5395):1827. PMID: 9804556.

3. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016 Aug 6;388(10044):576-85. doi: 10.1016/S0140-6736(16)30169-6. Epub 2016 Jun 9. PMID: 27291994.

4. Mascetti VL, Pedersen RA. Human-Mouse Chimerism Validates Human Stem Cell Pluripotency. Cell Stem Cell. 2016 Jan 7;18(1):67-72. doi: 10.1016/j.stem.2015.11.017. Epub 2015 Dec 17. PMID: 26712580; PMCID: PMC4712187.

5. Anastasiadis K, Antonitsis P, Westaby S, Reginald A, Sultan S, Doumas A, Efthimiadis G, Evans MJ. Implantation of a Novel Allogeneic Mesenchymal Precursor Cell Type in Patients with Ischemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting: an Open Label Phase IIa Trial. J Cardiovasc Transl Res. 2016 Jun;9(3):202-213. doi: 10.1007/s12265-016-9686-0. Epub 2016 Apr 1. Erratum in: J Cardiovasc Transl Res. 2021 Jun;14(3):587-588. PMID: 27037806.

6. Plaza Reyes A, Petrus-Reurer S, Padrell Sánchez S, Kumar P, Douagi I, Bartuma H, Aronsson M, Westman S, Lardner E, André H, Falk A, Nandrot EF, Kvanta A, Lanner F. Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells. Nat Commun. 2020 Mar 30;11(1):1609. doi: 10.1038/s41467-020-15326-5. Erratum in: Nat Commun. 2020 May 6;11(1):2346. Erratum in: Nat Commun. 2020 Jul 9;11(1):3504. PMID: 32231223; PMCID: PMC7105463.

7. Leong J, Hong YT, Wu YF, Ko E, Dvoretskiy S, Teo JY, Kim BS, Kim K, Jeon H, Boppart M, Yang YY, Kong H. Surface Tethering of Inflammation-Modulatory Nanostimulators to Stem Cells for Ischemic Muscle Repair. ACS Nano. 2020 May 26;14(5):5298-5313. doi: 10.1021/acsnano.9b04926. Epub 2020 Apr 13. PMID: 32243129; PMCID: PMC8274413.

8. https://www.ncchd.go.jp/en/news/2020/20200521-e.pdf

9. Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D, Morikawa K, Teles D, Yazawa M, Vunjak-Novakovic G. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018 Apr;556(7700):239-243. doi: 10.1038/s41586-018-0016-3. Epub 2018 Apr 4. Erratum in: Nature. 2019 Aug;572(7769):E16-E17. PMID: 29618819; PMCID: PMC5895513.

10. Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, Kato J, Sasaki Y, Ishiai S, Ito YM, Namioka A, Namioka T, Nakazaki M, Kataoka-Sasaki Y, Onodera R, Oka S, Sasaki M, Waxman SG, Kocsis JD. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021 Apr;203:106565. doi: 10.1016/j.clineuro.2021.106565. Epub 2021 Feb 18. PMID: 33667953.

11. S. Palma-Tortosa, D. Tornero, M. Grønning Hansen, E. Monni, M. Hajy, S. Kartsivadze, S. Aktay, O. Tsupykov, M. Parmar, K. Deisseroth, et al. Activity in grafted human iPS cell-derived cortical neurons integrated in stroke-injured rat brain regulates motor behavior. Proc Natl Acad Sci U S A, 117 (2020), pp. 9094-9100

 

Loading...
Join the Discussion